Novo Nordisk CEO Says Obesity Drug Market Won’t Be Winner-Take-All — BigGo Finance
Novo Nordisk (NVO) CEO Mike Doustdar pushed back Wednesday against the prevailing investor narrative that the booming obesity…
Novo Nordisk Battles Price War on Two Fronts: Implant Innovation and Medicare Access vs. Margin Eros
Novo Nordisk finds itself navigating a sharply divided landscape. On one side, a promising pipeline of next-generation treatments…
Novo Nordisk’s Rally Faces a Test: Medicare Tailwinds Meets Analyst Caution and a Billion-Dollar P
The past month has brought some much-needed relief to Novo Nordisk shareholders. After shedding nearly a third of…
Novo Nordisk’s Pill Lands in the UK With 70,000 Waiting as Medicare Push Opens a New US Front
Novo Nordisk is firing on two growth cylinders. The Danish pharma giant has just launched its oral Wegovy…
Novo Nordisk’s Wegovy Broadens Its Reach: UK MASH Nod, Medicare Push, and a Billion-Dollar Parent
Novo Nordisk’s bestselling GLP-1 drug is no longer tethered solely to obesity. The Danish pharma giant has locked…
Novo Nordisk’s Pill and Medicare Double Act Fails to Silence Analyst Doubts
A dual catalyst – the UK launch of an oral version of Wegovy and a fresh US Medicare…
Can Medicare Bridge Help Novo Nordisk Defend Its GLP-1 Leadership?
Novo Nordisk NVO has received another commercial boost as the Medicare GLP-1 Bridge program officially went live on July…
Eligible Houston-area Medicare recipients can now get GLP-1 weight-loss drugs for $50 a month
Millions of Medicare beneficiaries could soon pay significantly less for popular GLP-1 weight loss medications under a new…
Novo Nordisk’s Medicare Bridge Mixes Clinical Muscle with a Buyback Boost
The Medicare GLP-1 Bridge program that opens on July 1, 2026, hands Novo Nordisk a potential turning point…
Trump low-cost GLP-1 plan a likely boost for Eli Lilly, Novo Nordisk
WASHINGTON — The Trump administration’s grand bargain with drugmakers on GLP-1s was based on a simple premise: lower…
Novo Nordisk’s Landmark Week: Medicare Enters Weight-Loss Market and UK Approves Oral Wegovy
The Danish drugmaker enters uncharted territory this week with two regulatory milestones converging simultaneously. Starting Tuesday, July 1…
Novo Nordisk’s Rally Faces a Pivotal Week of Data, Buybacks, and Medicare Tailwinds
The Danish drugmaker’s stock has clawed back nearly 40% from its March trough of €30.25, closing last week…